FMCG major Dabur today said the products on which US Food and Drug Administration has issued import alerts were unauthorised exports by an independent exporter and the company has taken up the matter with the health regulator.
Reacting to media reports that said the company’s two Himachal Pradesh based plants are under the scanner of US FDA, Dabur said it was an “unauthorised export” by an independent trader “without any consent or knowledge of Dabur India Ltd”.
“The products mentioned were part of an unauthorised export by an independent trader without any consent or knowledge of Dabur India Ltd. Dabur did not export these products from India to the US. Dabur has already taken up the matter with the US FDA,” the company said in a statement.
When contacted, a Dabur spokesperson said that the company does not export to the US market.
According to the reports, US FDA has put two plants of Dabur – Baddi and Nalagarh in Himachal Pradesh – under import alert.
An import alert allows FDA to detain, without physically examining, products that either have or potentially could violate the United States’ Food, Drug, and Cosmetic Act.
In Baddi, Dabur manufactures oral hygiene products such as Meswak toothpaste while at its Nalagarh facility, skin care products such as fairness cream bleach are made.
Last month, US FDA had issued import alert against Indian drug firm Wockhardt on its manufacturing facility near Aurangabad.
Shares of Dabur were trading at Rs 152.80 per scrip in the afternoon trade at BSE, up 1.56 per cent from its previous close.